Apexigen and the Nordic Society of Gynaecological Oncology – Clinical Trial Unit Announce Collaborative Phase 2 Study of Sotigalimab (APX005M) in Combination Therapy for Ovarian Cancer

NEXT STORY
BriaCell Therapeutics Expands Breast Cancer Platform Technology into Prostate, Melanoma, and Lung Cancers
PREV STORY
Paratek Pharmaceuticals Announces Initiation of Phase 2b Study in Nontuberculous Mycobacterial (NTM) Pulmonary Disease Caused by Mycobacterium abscessus Complex (MABc) with NUZYRA® (omadacycline)
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Chi-Med Announces First Commercial Launch of Fruquintinib Capsules (Elunate®)

LONDON, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) ...

author_avatar
NASDAQ Market News

Zai Lab Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Greenshoe Option

author_avatar
NASDAQ Market News

ARASENS trial with darolutamide in combination with docetaxel and androgen deprivation therapy meets primary endpoint of significantly increasing overall survival in patients with metastatic hormone-sensitive prostate cancer

author_avatar
NASDAQ Market News